A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating advanced rectal ...

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why ...

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why ...

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...

Programmed death-ligand 1 (PD-L1) is a crucial immune checkpoint ligand that inhibits antitumor immunity by engaging PD-1 on T cells, and checkpoint blockade has become a pillar of anticancer therapy.

The market opportunities in the PD-1 Resistant Head and Neck Cancer sector include the rising need for salvage therapies due to resistance to standard treatments, the proliferation of next-gen ...

New results from a clinical trial co-led by UCLA investigators demonstrate how treating desmoplastic melanoma, a rare and ...